Table 2.

Association between neutrophil‐to‐lymphocyte ratio (NLR) and pathological variables

Variable	No. of patients (n = 994)	NLR (Mean ± SD)	P‐value	Low	High	P‐value
pT stage	958 (100%)		0.650			0.115
pT2	660 (68.9%)	2.40 ± 2.35		362 (69.9%)	298 (67.7%)
pT3	274 (28.6%)	2.29 ± 1.90		148 (28.6%)	126 (28.6%)
pT4	24 (2.5%)	2.67 ± 1.45		8 (1.5%)	16 (3.7%)
Gleason grade	940 (100%)		0.312			0.255
≤3 + 3	180 (19.1%)	2.37 ± 2.04		99 (19.6%)	81 (18.6%)
3 + 4	330 (35.1%)	2.25 ± 1.83		185 (36.6%)	145 (33.4%)
4 + 3	170 (18.1%)	2.65 ± 3.36		95 (18.8%)	75 (17.2%)
≥4 + 4	260 (27.7%)	2.38 ± 1.84		126 (25.0%)	134 (30.8%)
Preoperation PSA level (ng/mL)	958 (100%)		0.111			0.946
PSA≤10	327 (34.1%)	2.21 ± 1.70		178 (34.3%)	149 (33.9%)
PSA>10	631 (65.9%)	2.45 ± 2.43		341 (65.7%)	290 (66.1%)
pN stage	778 (100%)		0.268			0.680
pN0	721 (92.7%)	2.39 ± 2.33		395 (92.3%)	326 (93.1%)
pN+	57 (7.3%)	2.76 ± 3.18		33 (7.7%)	24 (6.9%)
Prostate capsule invasion	972 (100%)		0.376			0.047
Negative	723 (74.4%)	2.33 ± 2.25		405 (77.0%)	318 (71.3%)
Positive	249 (25.6%)	2.47 ± 2.04		121 (23.0%)	128 (28.7%)
Seminal vesicle invasion	971 (100%)		0.800			0.052
Negative	817 (84.1%)	2.38 ± 2.27		453 (86.3%)	364 (81.6%)
Positive	154 (15.9%)	2.33 ± 1.81		72 (13.7%)	82 (18.4%)
Surgical margin	971 (100%)		0.772			0.166
Negative	627 (64.6%)	2.38 ± 2.28		247 (58.1%)	280 (62.8%)
Positive	344 (35.4%)	2.34 ± 2.04		178 (41.9%)	166 (37.2%)
Nerve invasion	971 (100%)		0.710			0.733
Negative	649 (66.8%)	2.35 ± 2.16		349 (66.3%)	300 (67.4%)
Positive	322 (33.2%)	2.40 ± 2.28		177 (33.7%)	145 (32.6%)

PSA, prostate specific antigen.